Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4945225 | 0.76 | KMT2A (0.50) | SMN1; SMN2ALDH1A1TSHRHPGDLMNA | |
| SCHEMBL4944614 | 0.74 | KDM4E (0.34) | RAB9ASMN1; SMN2ALDH1A1PKMMAPT | |
| SCHEMBL4943994 | 0.73 | CYP3A4 (0.49) | SMN1; SMN2ALDH1A1MAPTTSHRLMNA | |
| SCHEMBL1544456 | 0.72 | SMN1; SMN2 (0.55) | RAB9ASMN1; SMN2ALDH1A1PKMMAPT | |
| SCHEMBL17712783 | 0.67 | RAB9A (0.63) | RAB9ASMN1; SMN2ALDH1A1PKMMAPT | |
| SCHEMBL4944242 | 0.66 | NPC1 (0.33) | RAB9AMAPTHPGDHSD17B10LMNA | |
| SCHEMBL4946170 | 0.65 | MEN1 (0.36) | RAB9ASMN1; SMN2ALDH1A1MAPTHPGD | |
| SCHEMBL1543755 | 0.64 | CYP3A4 (0.59) | RAB9ASMN1; SMN2ALDH1A1PKMMAPT | |
| SCHEMBL5482811 | 0.64 | ALDH1A1 (0.38) | SMN1; SMN2ALDH1A1PKMMAPTTSHR | |
| SCHEMBL4944606 | 0.62 | RAB9A (0.41) | RAB9ASMN1; SMN2ALDH1A1PKMMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045571-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045571-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | GRM5, GRIK5, GRM2 | RAB9A 1926/4885SMN1; SMN2 1409/4885ALDH1A1 3875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.